Company / CIK 0001515673
Ultragenyx Pharmaceutical Inc.
- Ticker
- RARE
- Size, estimated from filings
- Small cap ($300M – $2B)
- Insiders on file
- 15
- Members of Congress who traded it
- 1
- Federal contracts on record
- none matched
- Lobbying filings on record
- 21
- SEC filings
- EDGAR ↗
- Latest trade on record
- October 15, 2026
Ultragenyx Pharmaceutical Inc. (RARE) has 15 insiders on file who disclosed 67 transactions in the last 12 months (0 open-market buys, 30 sales, about $3.8M at reported prices), and 3 congressional trades in its stock are on record. No federal contract award that started in the last 180 days was found for a recipient with exactly this name, and 15 lobbying filings naming it as client report $1.5M in 2026.
Ultragenyx Pharmaceutical Inc. in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
BoughtSold
8 people account for the disclosed buying and selling in Ultragenyx Pharmaceutical Inc. over the last 12 months; the most active is KAKKIS EMIL D with $1.2M.
Lobbying spend by quarter
How much has Ultragenyx Pharmaceutical Inc. reported spending on federal lobbying?
Ultragenyx Pharmaceutical Inc. reported $2.0M in lobbying over the last eight quarters, from filings matched by exact company name.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Horn Howard | Chief Financial Officer | 16 | 0 | 13 | October 19, 2026 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 7 | 0 | 5 | September 15, 2026 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 8 | 0 | 5 | August 4, 2026 |
| Dunsire Deborah | Director | 2 | 0 | 0 | July 23, 2026 |
| Sanders Corazon (Corsee) D. | Director | 3 | 0 | 1 | June 15, 2026 |
| WELCH DANIEL G | Director | 2 | 0 | 0 | May 18, 2026 |
| NARACHI MICHAEL | Director | 2 | 0 | 0 | May 18, 2026 |
| Ray Amrit | Director | 2 | 0 | 0 | May 18, 2026 |
| SULIMAN SHEHNAAZ | Director | 3 | 0 | 1 | May 18, 2026 |
| Fust Matthew K | Director | 2 | 0 | 0 | May 18, 2026 |
| Crombez Eric | EVP and Chief Medical Officer | 5 | 0 | 2 | May 6, 2026 |
| Huang Dennis Karl | See Remarks | 4 | 0 | 1 | April 20, 2026 |
| KAKKIS EMIL D | President & CEO | 4 | 0 | 1 | April 20, 2026 |
| Harris Erik | EVP & Chief Commercial Officer | 4 | 0 | 1 | April 20, 2026 |
| Pinion John Richard | See Remarks | 4 | 0 | 1 | April 20, 2026 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Members of Congress who traded RARE
From periodic transaction reports that name the company's stock. Amounts are the sums of the ranges as filed. Every row is on the RARE page.
| Member | Seat | Trades | Bought | Sold | Range as filed | Latest |
|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Representative (CA, District 31), Democrat | 3 | 3 | 0 | $3,003–$45K | September 29, 2026 |
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Horn Howard | RARE | Sell S | October 15, 2026 | October 19, 2026 | 4d | 7,066 | $15 | $108K | Form 4 ↗ | ||
| Huizenga Theodore Alan | RARE | Sell S | September 15, 2026 | September 15, 2026 | 0d | 1,283 | $14 | $17K | 10b5-1 plan | Form 4 ↗ | |
| Huizenga Theodore Alan | RARE | Sell S | September 3, 2026 | September 8, 2026 | 5d | 161 | $14 | $2,252 | late | Form 4 ↗ | |
| Parschauer Karah Herdman | RARE | Sell S | August 3, 2026 | August 4, 2026 | 1d | 1,900 | $25 | $47K | 10b5-1 plan | Form 4 ↗ | |
| Horn Howard | RARE | Sell S | August 3, 2026 | August 4, 2026 | 1d | 4,696 | $25 | $117K | 10b5-1 plan | Form 4 ↗ | |
| Horn Howard | RARE | Sell S | July 1, 2026 | July 6, 2026 | 5d | 4,698 | $33 | $156K | late10b5-1 plan | Form 4 ↗ | |
| Sanders Corazon (Corsee) D. | RARE | Sell S | June 15, 2026 | June 15, 2026 | 0d | 2,000 | $25 | $50K | Form 4 ↗ | ||
| Parschauer Karah Herdman | RARE | Sell S | June 15, 2026 | June 15, 2026 | 0d | 1,899 | $25 | $47K | 10b5-1 plan | Form 4 ↗ | |
| Horn Howard | RARE | Sell S | June 1, 2026 | June 1, 2026 | 0d | 4,653 | $24 | $111K | 10b5-1 plan | Form 4 ↗ | |
| Fust Matthew K | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 14,058 | — | — | derivative | Form 4 ↗ | |
| Fust Matthew K | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 7,751 | — | — | Form 4 ↗ | ||
| SULIMAN SHEHNAAZ | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 14,058 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| SULIMAN SHEHNAAZ | RARE | Sell S | May 18, 2026 | May 18, 2026 | 0d | 5,740 | $25 | $144K | 10b5-1 plan | Form 4 ↗ | |
| SULIMAN SHEHNAAZ | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 7,751 | — | — | 10b5-1 plan | Form 4 ↗ | |
| Ray Amrit | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 14,058 | — | — | derivative | Form 4 ↗ | |
| Ray Amrit | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 7,751 | — | — | Form 4 ↗ | ||
| Sanders Corazon (Corsee) D. | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 14,058 | — | — | derivative | Form 4 ↗ | |
| Sanders Corazon (Corsee) D. | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 7,751 | — | — | Form 4 ↗ | ||
| NARACHI MICHAEL | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 14,058 | — | — | derivative | Form 4 ↗ | |
| NARACHI MICHAEL | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 7,751 | — | — | Form 4 ↗ | ||
| WELCH DANIEL G | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 14,058 | — | — | derivative | Form 4 ↗ | |
| WELCH DANIEL G | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 7,751 | — | — | Form 4 ↗ | ||
| Dunsire Deborah | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 14,058 | — | — | derivative | Form 4 ↗ | |
| Dunsire Deborah | RARE | Other A | May 14, 2026 | May 18, 2026 | 4d | 7,751 | — | — | Form 4 ↗ | ||
| Crombez Eric | RARE | Sell S | May 5, 2026 | May 6, 2026 | 1d | 344 | $25 | $8,586 | Form 4 ↗ | ||
| Horn Howard | RARE | Sell S | May 1, 2026 | May 4, 2026 | 3d | 4,683 | $25 | $117K | 10b5-1 plan | Form 4 ↗ | |
| Huizenga Theodore Alan | RARE | Other A | April 22, 2026 | April 24, 2026 | 2d | 7,348 | — | — | derivative | Form 4 ↗ | |
| Huizenga Theodore Alan | RARE | Other A | April 22, 2026 | April 24, 2026 | 2d | 20,241 | — | — | Form 4 ↗ | ||
| KAKKIS EMIL D | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 132,693 | — | — | derivative | Form 4 ↗ | |
| KAKKIS EMIL D | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 76,745 | — | — | Form 4 ↗ | ||
| Huang Dennis Karl | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 79,936 | — | — | derivative | Form 4 ↗ | |
| Huang Dennis Karl | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 23,116 | — | — | Form 4 ↗ | ||
| Pinion John Richard | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 79,936 | — | — | derivative | Form 4 ↗ | |
| Pinion John Richard | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 23,116 | — | — | Form 4 ↗ | ||
| Parschauer Karah Herdman | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 49,960 | — | — | derivative | Form 4 ↗ | |
| Parschauer Karah Herdman | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 28,895 | — | — | Form 4 ↗ | ||
| Harris Erik | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 49,960 | — | — | derivative | Form 4 ↗ | |
| Harris Erik | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 28,895 | — | — | Form 4 ↗ | ||
| Crombez Eric | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 59,952 | — | — | derivative | Form 4 ↗ | |
| Crombez Eric | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 34,674 | — | — | Form 4 ↗ | ||
| Horn Howard | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 59,952 | — | — | derivative | Form 4 ↗ | |
| Horn Howard | RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 34,674 | — | — | Form 4 ↗ | ||
| Horn Howard | RARE | Sell S | April 1, 2026 | April 2, 2026 | 1d | 4,683 | $21 | $98K | 10b5-1 plan | Form 4 ↗ | |
| Parschauer Karah Herdman | RARE | Sell S | March 10, 2026 | March 10, 2026 | 0d | 3,508 | $23 | $80K | Form 4 ↗ | ||
| Parschauer Karah Herdman | RARE | Sell S | March 6, 2026 | March 10, 2026 | 4d | 6,018 | $21 | $129K | Form 4 ↗ | ||
| Pinion John Richard | RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 10,029 | $23 | $229K | Form 4 ↗ | ||
| Pinion John Richard | RARE | Other A | March 1, 2026 | March 3, 2026 | 2d | 11,137 | — | — | Form 4 ↗ | ||
| Harris Erik | RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 10,539 | $23 | $240K | Form 4 ↗ | ||
| Harris Erik | RARE | Other A | March 1, 2026 | March 3, 2026 | 2d | 11,643 | — | — | Form 4 ↗ | ||
| KAKKIS EMIL D | RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 54,404 | $23 | $1.2M | Form 4 ↗ | ||
| KAKKIS EMIL D | RARE | Other A | March 1, 2026 | March 3, 2026 | 2d | 71,177 | — | — | Form 4 ↗ | ||
| Parschauer Karah Herdman | RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 8,135 | $23 | $185K | Form 4 ↗ | ||
| Parschauer Karah Herdman | RARE | Other A | March 1, 2026 | March 3, 2026 | 2d | 11,137 | — | — | Form 4 ↗ | ||
| Huizenga Theodore Alan | RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 1,632 | $23 | $37K | Form 4 ↗ | ||
| Huizenga Theodore Alan | RARE | Sell F | March 2, 2026 | March 3, 2026 | 1d | 148 | $23 | $3,462 | Form 4 ↗ | ||
| Horn Howard | RARE | Sell S | March 3, 2026 | March 3, 2026 | 0d | 1,635 | $22 | $37K | 10b5-1 plan | Form 4 ↗ | |
| Horn Howard | RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 3,119 | $23 | $70K | 10b5-1 plan | Form 4 ↗ | |
| Horn Howard | RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 5,290 | $23 | $121K | 10b5-1 plan | Form 4 ↗ | |
| Horn Howard | RARE | Other A | March 1, 2026 | March 3, 2026 | 2d | 6,143 | — | — | 10b5-1 plan | Form 4 ↗ | |
| Crombez Eric | RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 7,029 | $23 | $160K | Form 4 ↗ | ||
| Crombez Eric | RARE | Other A | March 1, 2026 | March 3, 2026 | 2d | 11,643 | — | — | Form 4 ↗ | ||
| Huang Dennis Karl | RARE | Sell F | March 2, 2026 | March 3, 2026 | 1d | 999 | $23 | $23K | Form 4 ↗ | ||
| Huang Dennis Karl | RARE | Other A | March 1, 2026 | March 3, 2026 | 2d | 11,137 | — | — | Form 4 ↗ | ||
| Horn Howard | RARE | Sell S | February 2, 2026 | February 3, 2026 | 1d | 3,061 | $24 | $72K | 10b5-1 plan | Form 4 ↗ | |
| Horn Howard | RARE | Sell S | January 2, 2026 | January 5, 2026 | 3d | 3,150 | $23 | $72K | 10b5-1 plan | Form 4 ↗ | |
| Huizenga Theodore Alan | RARE | Sell S | December 29, 2025 | December 30, 2025 | 1d | 85 | $34 | $2,922 | Form 4 ↗ | ||
| Horn Howard | RARE | Sell S | December 10, 2025 | December 11, 2025 | 1d | 3,081 | $36 | $112K | 10b5-1 plan | Form 4 ↗ | |
| Horn Howard | RARE | Sell S | October 13, 2025 | October 14, 2025 | 1d | 7,942 | $32 | $250K | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "Ultragenyx Pharmaceutical Inc.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
| Period | Registrant | Primary issue | Amount | Source |
|---|---|---|---|---|
| 2026 Q3 | ULTRAGENYX PHARMACEUTICAL INC. | Health Issues | $280,000 | LDA ↗ |
| 2026 Q3 | FORBES-TATE | Health Issues | $20,000 | LDA ↗ |
| 2026 Q2 | ULTRAGENYX PHARMACEUTICAL INC. | Health Issues | $390,000 | LDA ↗ |
| 2026 Q2 | MILLER STRATEGIES, LLC | Medical/Disease Research/Clinical Labs | $140,000 | LDA ↗ |
| 2026 Q2 | ALPINE GROUP PARTNERS, LLC. | Health Issues | $60,000 | LDA ↗ |
| 2026 Q2 | MEHLMAN CONSULTING, INC. | Health Issues | $60,000 | LDA ↗ |
| 2026 Q2 | FORBES-TATE | Health Issues | $30,000 | LDA ↗ |
| 2026 Q1 | ULTRAGENYX PHARMACEUTICAL INC. | Health Issues | $440,000 | LDA ↗ |
| 2026 Q1 | MEHLMAN CONSULTING, INC. | Health Issues | $60,000 | LDA ↗ |
| 2026 Q1 | ALPINE GROUP PARTNERS, LLC. | Health Issues | $40,000 | LDA ↗ |
| 2026 Q1 | FORBES-TATE | Health Issues | $10,000 | LDA ↗ |
| 2026 Q1 | MILLER STRATEGIES, LLC | Medical/Disease Research/Clinical Labs | — | LDA ↗ |
| 2026 Q1 | FORBES-TATE | Health Issues | — | LDA ↗ |
| 2026 Q1 | ALPINE GROUP PARTNERS, LLC. | Health Issues | — | LDA ↗ |
| 2026 Q1 | AVIVA STRATEGIES (FKA MGB CONSULTING) | Health Issues | — | LDA ↗ |
| 2025 Q4 | ULTRAGENYX PHARMACEUTICAL INC. | Health Issues | $130,000 | LDA ↗ |
| 2025 Q4 | MEHLMAN CONSULTING, INC. | Health Issues | $60,000 | LDA ↗ |
| 2025 Q4 | AVIVA STRATEGIES (FKA MGB CONSULTING) | Health Issues | $38,000 | LDA ↗ |
| 2025 Q3 | ULTRAGENYX PHARMACEUTICAL INC. | Health Issues | $140,000 | LDA ↗ |
| 2025 Q3 | MEHLMAN CONSULTING, INC. | Health Issues | $60,000 | LDA ↗ |
| 2025 Q3 | AVIVA STRATEGIES (FKA MGB CONSULTING) | Health Issues | $38,000 | LDA ↗ |
Related companies
Companies whose stock was traded by the same people who traded RARE, by number of filers in common. It shows overlap in public filings and nothing else.
- MCKESSON CORP MCK 2 filers in common
- CrowdStrike Holdings, Inc. CRWD 1 filer in common
- Cloudflare, Inc. NET 1 filer in common
- Uber Technologies, Inc UBER 1 filer in common
- Datadog, Inc. DDOG 1 filer in common
- CARVANA CO. CVNA 1 filer in common
- Arista Networks, Inc. ANET 1 filer in common
- Credo Technology Group Holding Ltd CRDO 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Lobbying disclosure reports Reports are due about 20 days after each quarter ends.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| House Clerk, periodic transaction reports | 3 | 3 | March 9, 2026 | October 12, 2026 | House Clerk search |
| SEC EDGAR, Form 4 | 41 | 68 | October 14, 2025 | October 19, 2026 | Form 4 list on EDGAR |
| Lobbying disclosure filings | 21 filings | — | — | — | LDA.gov search |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.